FY2024 Earnings Estimate for KZR Issued By William Blair

Kezar Life Sciences, Inc. (NASDAQ:KZR) – Analysts at William Blair boosted their FY2024 earnings per share (EPS) estimates for Kezar Life Sciences in a research note issued on Wednesday, November 13th. William Blair analyst M. Phipps now forecasts that the company will post earnings of ($2.06) per share for the year, up from their prior forecast of ($12.50). William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($6.47) per share. William Blair also issued estimates for Kezar Life Sciences’ Q4 2024 earnings at ($2.81) EPS, Q1 2025 earnings at ($2.73) EPS, Q2 2025 earnings at ($2.75) EPS, Q3 2025 earnings at ($2.78) EPS, Q4 2025 earnings at ($2.80) EPS, FY2025 earnings at ($11.06) EPS, FY2026 earnings at ($11.86) EPS and FY2027 earnings at ($12.84) EPS.

Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($2.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.03) by $0.25.

Other analysts also recently issued research reports about the company. HC Wainwright reaffirmed a “neutral” rating on shares of Kezar Life Sciences in a research note on Monday, October 14th. Wells Fargo & Company cut their price objective on Kezar Life Sciences from $20.00 to $11.00 and set an “equal weight” rating on the stock in a report on Thursday.

Kezar Life Sciences Trading Down 0.8 %

KZR opened at $7.46 on Monday. The firm’s fifty day moving average is $7.20 and its two-hundred day moving average is $6.82. The firm has a market cap of $54.46 million, a PE ratio of -0.57 and a beta of 0.22. Kezar Life Sciences has a twelve month low of $5.20 and a twelve month high of $11.35. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.58 and a current ratio of 7.65.

Institutional Trading of Kezar Life Sciences

Institutional investors have recently modified their holdings of the company. Mackenzie Financial Corp acquired a new stake in Kezar Life Sciences in the 2nd quarter valued at approximately $35,000. XTX Topco Ltd raised its holdings in shares of Kezar Life Sciences by 256.1% in the third quarter. XTX Topco Ltd now owns 52,148 shares of the company’s stock valued at $40,000 after purchasing an additional 37,504 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Kezar Life Sciences in the second quarter worth $63,000. BNP Paribas Financial Markets boosted its holdings in Kezar Life Sciences by 35.4% during the first quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company’s stock worth $247,000 after purchasing an additional 71,543 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Kezar Life Sciences by 15.0% in the third quarter. Geode Capital Management LLC now owns 626,912 shares of the company’s stock valued at $485,000 after purchasing an additional 81,678 shares in the last quarter. 67.90% of the stock is currently owned by institutional investors.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.